Selecta Biosciences Inc
NASDAQ:SELB
Intrinsic Value
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention... [ Read More ]
The intrinsic value of one SELB stock under the Base Case scenario is 1.0582 USD. Compared to the current market price of 0.7465 USD, Selecta Biosciences Inc is Undervalued by 29%.
Valuation Backtest
Selecta Biosciences Inc
Run backtest to discover the historical profit from buying and selling SELB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Selecta Biosciences Inc
Current Assets | 122.7m |
Cash & Short-Term Investments | 112m |
Receivables | 6.4m |
Other Current Assets | 4.3m |
Non-Current Assets | 16.8m |
Long-Term Investments | 2m |
PP&E | 13.4m |
Other Non-Current Assets | 1.4m |
Current Liabilities | 29.4m |
Accounts Payable | 267k |
Accrued Liabilities | 14.6m |
Other Current Liabilities | 14.5m |
Non-Current Liabilities | 44.7m |
Long-Term Debt | 13.8m |
Other Non-Current Liabilities | 30.9m |
Earnings Waterfall
Selecta Biosciences Inc
Revenue
|
48.7m
USD
|
Operating Expenses
|
-95.8m
USD
|
Operating Income
|
-47.1m
USD
|
Other Expenses
|
12.1m
USD
|
Net Income
|
-35.1m
USD
|
Free Cash Flow Analysis
Selecta Biosciences Inc
What is Free Cash Flow?
SELB Profitability Score
Profitability Due Diligence
Selecta Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Selecta Biosciences Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
SELB Solvency Score
Solvency Due Diligence
Selecta Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Selecta Biosciences Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SELB Price Targets Summary
Selecta Biosciences Inc
Ownership
SELB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SELB Price
Selecta Biosciences Inc
Average Annual Return | 13.57% |
Standard Deviation of Annual Returns | 15.2% |
Max Drawdown | -87% |
Market Capitalization | 114.5m USD |
Shares Outstanding | 153 427 008 |
Percentage of Shares Shorted | 7.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
Contact
IPO
Employees
Officers
The intrinsic value of one SELB stock under the Base Case scenario is 1.0582 USD.
Compared to the current market price of 0.7465 USD, Selecta Biosciences Inc is Undervalued by 29%.